16 terminated. 16 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Terminated 16 |
| Phase 1 | 2 | Terminated 2 |
Follow Interferon-alpha: new trials by email Literature Review of Interferon-alpha trials Research Report on Interferon-alpha
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy Peginterferon Alfa-2A 180 MCG/ML Injectable Solution - Membranous Nephropathy | Phase 2 | Terminated | Centre Hospitalier Universitaire de Nice | 4 | 2023-09-14 | 2026-06-18 |
| Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis Peginterferon alfa-2a - Myelofibrosis | Phase 2 | Terminated | Weill Medical College of Cornell University | 8 | 2013-01-01 | 2018-07-24 |
| Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2) - Colorectal Cancer, Colorectal Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 15 | 2012-10-01 | 2023-10-27 |
| Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis interferon-alpha lozenges, placebo lozenges - Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis | Phase 2 | Terminated | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | 1 | 2008-06-01 | 2012-04-24 |
| A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC) - Renal Cell Carcinoma | Phase 2 | Terminated | Endocyte | 12 | 2007-06-01 | 2012-03-08 |
| Chemoradiation in Locally Advanced Pancreatic Cancer recombinant interferon alfa, cisplatin, fluorouracil - Pancreatic Cancer | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 23 | 2005-01-01 | 2017-12-28 |
| Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers allogeneic GM-CSF-secreting breast cancer vaccine, recombinant interferon alfa, cyclophosphamide - Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Terminated | Wiseman Research Initiatives LLC | 24 | 2004-11-01 | 2018-02-05 |
| Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer sorafenib tosylate, recombinant interferon alfa, laboratory biomarker analysis - Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 40 | 2004-10-01 | 2013-07-02 |
| Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma recombinant interferon alfa, thalidomide, laboratory biomarker analysis - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 35 | 2001-07-01 | 2013-01-25 |
| Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia recombinant interferon alfa, imatinib mesylate - Leukemia | Phase 2 | Terminated | OHSU Knight Cancer Institute | 25 | 2001-04-01 | 2025-08-22 |
| Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia busulfan, cyclophosphamide, filgrastim - Leukemia | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 2000-08-01 | 2017-11-29 | |
| Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia cyclophosphamide, filgrastim, recombinant interferon alfa - Leukemia | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 22 | 2000-08-01 | 2017-11-29 |
| Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma carmustine, cyclophosphamide, dexamethasone - Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 87 | 2000-08-01 | 2017-11-29 |
| Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer recombinant interferon alfa, cisplatin, fluorouracil - Esophageal Cancer | Phase 2 | Terminated | Northwestern University | 1999-10-01 | 2012-06-12 | |
| Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma BCG vaccine, autologous tumor cell vaccine, recombinant interferon alfa - Melanoma (Skin) | Phase 2 | Terminated | AVAX Technologies | 425 | 1998-12-01 | 2015-12-03 |
| Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia recombinant interferon alfa, sargramostim - Leukemia | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 48 | 1998-02-01 | 2011-07-20 |
Leukemia (4) · Leukemia, Myeloid, Chronic-Phase (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Carcinoma, Renal Cell (2) · Neoplasm Metastasis (2) · Adenocarcinoma Of Esophagus (1) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Chronic Cough (1) · Colorectal Neoplasms (1) · Cough (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Glomerulonephritis, Membranous (1) · Leukemia, Myeloid, Accelerated Phase (1)
Masonic Cancer Center, University of Minnesota (4) · National Cancer Institute (NCI) (2) · AVAX Technologies (1) · Ainos, Inc. (f/k/a Amarillo Biosciences Inc. (1) · Centre Hospitalier Universitaire de Nice (1) · Endocyte (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Weill Medical College of Cornell University (1) · Wiseman Research Initiatives LLC (1)
United States (15) · France (1)
Catherine M. Verfaillie, MD (2) · Amer H Zureikat, MD (1) · Brian J. Druker, MD (1) · Charles L. Wiseman, MD, FACP (1) · Claudia Tellez, MD (1) · Daniel George (1) · Daniel J. Weisdorf, MD (1) · Edward W. Greeno, MD (1) · John Sweetenham (1) · Karen Doak (1) · Lorenz O Lutherer, MD, PhD (1) · Richard A Messmann, MD, MHS, BSc (1) · Richard J. Jones, MD (1) · Richard T Silver, M.D. (1)
P30CA006973 (1), U01CA099118 (1)